Pharmsynthesis

Pharmsynthesis is a Russian pharmaceutical company specializing in the development and production of drugs for treatment of socially significant diseases such as tuberculosis, HIV infection, oncology, diabetes and hepatitis. The company has been on the pharmaceutical market since 1997; its plants are located in Irkutsk, Ussuriysk, Tyumen, Bratsk and St. Petersburg.
Pharmsynthesis stock price chart
+38%
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential

Pharmsynthesis balance sheet

Report period2017 2018 2019 2020 2021 Q3 22
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Pharmsynthesis cash flows

Report period2017 2018 2019 2020 2021 Q3 22 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
EPS

Pharmsynthesis multipliers

Report period2017 2018 2019 2020 2021 Q3 22 TTM
P/E
E/P
P/B
P/S
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Pharmsynthesis profitability

Report period2017 2018 2019 2020 2021 Q3 22 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Pharmsynthesis assets
Pharmsynthesis cash flows
Pharmsynthesis dividends
0%

Pharmsynthesis shares

TickerNameTypeNominal valueISINPrice
LIFE:RMPharmsynthesisCommon shareRUB 5RU000A0JR514RUB 7.025
Share capital structure of Pharmsynthesis
Pharmsynthesis news
08.11.2022
Pharmsintez began offering 139,384,100 common shares, which is 46.3% of the share capital. Securities will be placed by public subscription at the price of ₽5.05 per share.
01.11.2022
Pharmsintez's RAS loss for 9 months of 2022 was ₽169.11 million, up 3.8 times from ₽44.005 million in the previous year. Revenue increased 65.1% to ₽247.05 million versus ₽149.62 million a year earlier.
19.09.2022
Pharmsintez's RAS loss for 6 months of 2022 was ₽117.285 million, up 2.8 times from ₽41.365 million in the previous year. Revenue increased 11.9% to ₽138.905 million versus ₽124.155 million a year earlier.
05.07.2022
Pharmsintez shareholders decided not to pay dividends for 2021
General information
Company namePharmsynthesis
Tags#pharmacy, #innovations of the russia
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressRossiyskaya Federaciya, Leningradskaya oblast, Vsevolozhskiy rayon
Mailing address188663 Rossiyskaya Federaciya, Leningradskaya oblast, Vsevolozhskiy rayon, gorodskoy poselok Kuzmolovskiy, stanciya Kapitolovo, 134 str. 1
CEOPrilezhaev Efim Aleksandrovich
Phone329-80-80
Websitepharmsynthez.com
Information disclosuree-disclosure.ru